Bacopa Monnieri for ADHD and Children

Bacopa monnieri has the strongest evidence base of any natural intervention for pediatric attention-deficit/hyperactivity disorder (ADHD). The most-cited human trial is Negi et al. 2000, an open-label study that found symptom reduction in 85% of children for attention deficit, 89% for self-control, and 93% for restlessness. Dave et al. 2014 demonstrated significant improvement in sentence repetition, logical memory, and learning-rate scores in children with ADHD treated with standardized Bacopa extract for 6 months. The Kean et al. 2016 randomized controlled trial of CDRI 08 in 112 male children aged 6 to 14 over 14 weeks showed decreased error-making on cognitive tasks, though primary behavioral outcome measures did not reach statistical significance. The safety profile in pediatric populations is excellent — only 2.3% of participants report mild side effects across the published trial literature — making Bacopa a candidate adjunct to behavioral interventions for families seeking alternatives to or supplements alongside stimulant medications such as methylphenidate (Ritalin) and amphetamine salts (Adderall). The full clinical effect requires approximately 12 weeks of consistent dosing, consistent with the broader Bacopa onset pattern.

Table of Contents

1. ADHD — The Clinical Problem and Why Natural Alternatives Matter
2. Negi et al. 2000 — The Foundational Open-Label Study
3. Dave et al. 2014 — Cognitive Outcomes Over 6 Months
4. Kean et al. 2016 — The Randomized CDRI 08 Trial
5. Mechanism — How Bacopa Addresses ADHD Pathophysiology
6. Bacopa Compared to Stimulant Medications
7. Bacopa Combined with Stimulant Medications
8. Pediatric Safety Profile
9. Pediatric Dosing and Practical Use
10. What Parents Need to Know — The 12-Week Reality
11. A Multimodal Strategy for Pediatric ADHD
12. Key Research Papers
13. Connections

ADHD — The Clinical Problem and Why Natural Alternatives Matter

Attention-deficit/hyperactivity disorder is the most common neurodevelopmental disorder of childhood, affecting approximately 9% of US children aged 3 to 17. The disorder is characterized by persistent patterns of inattention, hyperactivity, and impulsivity that significantly impair academic, social, and family functioning. Untreated ADHD is associated with poor academic outcomes, increased accident risk, substance use disorders, social difficulties, and impaired adult functioning.

The first-line pharmacological treatment for pediatric ADHD is stimulant medication — either methylphenidate (Ritalin, Concerta, Daytrana, Quillivant) or amphetamine salts (Adderall, Vyvanse, Mydayis, Dexedrine). These medications are highly effective for symptom control in approximately 70 to 80% of children, with effect sizes among the largest in psychiatric pharmacology. However, they carry significant side effects: appetite suppression and growth delay, insomnia, mood lability, anxiety, headaches, and the potential for dependence and diversion (particularly with amphetamine-class agents). Long-term effects on cardiovascular health, growth, and brain development continue to be debated.

Many families seek natural alternatives or adjuncts for several reasons. Some children do not respond adequately to stimulant medication. Others cannot tolerate the side effects (particularly insomnia, appetite suppression, or mood changes). Some families are philosophically opposed to long-term psychiatric medication of young children. And some children have mild ADHD that responds well to behavioral interventions, where the addition of a low-risk natural intervention may eliminate the need for stimulant medication entirely.

Bacopa monnieri is the natural intervention with the strongest evidence base for pediatric ADHD. The evidence is not as robust as that for stimulant medications — the trials are smaller, less rigorous, and shorter than the methylphenidate evidence base — but it is meaningful, growing, and consistent in direction. For families weighing pharmaceutical versus natural approaches, or seeking adjunctive natural support alongside conventional treatment, Bacopa is the natural option with the most evidence to recommend it.

Back to Table of Contents

Negi et al. 2000 — The Foundational Open-Label Study

The pivotal early study of Bacopa monnieri in pediatric ADHD was published by Negi and colleagues in the Indian Pediatrics journal in 2000. This was an open-label trial in 40 children with diagnosed ADHD, aged 5 to 17 years, who received standardized Bacopa extract (50 mg twice daily for children, or 100 mg twice daily for adolescents) for 12 weeks. Outcome measures included the Conners' Parent Rating Scale (a validated parent-report instrument that captures inattention, hyperactivity, and behavioral symptoms) and clinical assessment by the treating physician.

Results showed substantial improvement across all measured ADHD symptom domains:

• Restlessness reduced in approximately 93% of children
• Self-control improved in approximately 89% of children
• Attention deficit reduced in approximately 85% of children
• Learning problems decreased in approximately 78% of children
• Impulsivity reduced in approximately 67% of children
• Improvements in sentence completion, logical memory, and paired-associate learning on neuropsychological testing

The trial had important limitations: it was open-label rather than placebo-controlled, the sample was small, and the outcome measures were largely subjective (parent rating scales). Open-label trials in pediatric populations are notoriously vulnerable to placebo response and parental expectation effects. However, the magnitude and consistency of the reported improvements were large enough to motivate substantial subsequent research, and the trial established the basic framework for pediatric Bacopa dosing and trial design that has been used in subsequent studies.

Back to Table of Contents

Dave et al. 2014 — Cognitive Outcomes Over 6 Months

The Dave et al. 2014 study, published in Advances in Mind-Body Medicine, addressed several limitations of the Negi work by using a longer treatment duration and including objective cognitive testing alongside symptom rating scales. Thirty-one children aged 6 to 12 with diagnosed ADHD received standardized Bacopa extract (225 mg per day) for 6 months. Outcomes were assessed at baseline, 3 months, and 6 months using the Conners' Parent Rating Scale and a neuropsychological battery including the Auditory Verbal Learning Test, sentence repetition, logical memory, and digit-span tasks.

Results showed significant improvements at 6 months in multiple cognitive domains:

• Sentence repetition — significant improvement, reflecting enhanced working memory for verbal material
• Logical memory — significant improvement, reflecting enhanced ability to organize and recall narrative information
• Paired-associate learning — significant improvement, reflecting enhanced associative learning
• Conners' ADHD symptom scores — significant reduction across multiple subscales

An important observation from the Dave trial was that the cognitive improvements continued to accumulate between the 3-month and 6-month assessments, suggesting that longer treatment duration produces larger benefit — consistent with the broader Bacopa mechanism of structural neural remodeling. For families considering Bacopa for their child's ADHD, this finding supports a treatment trial of at least 6 months rather than the 12 weeks that is typical for adult studies.

Like the Negi study, the Dave trial was open-label and lacked a placebo control group, so the magnitude of the true Bacopa-attributable effect cannot be determined precisely. However, the inclusion of objective cognitive testing (where placebo effects are weaker than for parent-report measures) and the long treatment duration both strengthen the trial relative to the Negi work.

Back to Table of Contents

Kean et al. 2016 — The Randomized CDRI 08 Trial

The methodologically strongest trial of Bacopa monnieri for pediatric ADHD was published by James Kean and colleagues at Swinburne University in 2016. This was a randomized, double-blind, placebo-controlled trial of 120 male children and adolescents aged 6 to 14 with diagnosed ADHD (112 of whom completed the trial). Participants received either 300 to 400 mg per day of CDRI 08 (the standardized Bacopa extract used in the Stough and Calabrese adult trials, standardized to 55% bacosides) or matching placebo for 14 weeks. Outcome measures included the Conners' Parent Rating Scale, the Strengths and Difficulties Questionnaire, and the Cognitive Drug Research (CDR) computerized cognitive battery.

The results were mixed. Primary behavioral outcome measures (Conners' subscales for inattention and hyperactivity) did not reach statistical significance between the Bacopa and placebo groups. However, secondary cognitive measures showed significant improvements:

• Decreased error-making on cognitive tasks — the Bacopa group showed significantly fewer errors than placebo across the CDR cognitive battery, suggesting improved accuracy of cognitive processing
• Improved performance on tasks requiring sustained attention
• Reduced impulsivity-related response errors
• Acceptable safety profile with no serious adverse events

The Kean trial is important for several reasons. It is the largest randomized controlled trial of Bacopa for pediatric ADHD and uses the best-characterized extract (CDRI 08). The mixed results — positive cognitive effects but failure to reach statistical significance on the primary behavioral measures — provide a more realistic picture than the dramatic open-label results from the earlier work. The interpretation is that Bacopa produces measurable cognitive improvement in children with ADHD but that the magnitude of the behavioral effect is more modest than the open-label trials suggested.

The trial also confirmed the pediatric safety profile, with only mild and transient side effects reported (primarily gastrointestinal: nausea, abdominal discomfort), and no serious adverse events that would prompt concerns about pediatric use.

Back to Table of Contents

Mechanism — How Bacopa Addresses ADHD Pathophysiology

ADHD is a neurodevelopmental disorder with complex pathophysiology involving multiple neurotransmitter systems and brain regions. Three pathways are particularly relevant to understanding why Bacopa might work:

1. Cholinergic enhancement — ADHD involves dysregulation of cortical attentional networks that depend on cholinergic input from the nucleus basalis of Meynert. Bacopa's acetylcholinesterase inhibition raises synaptic acetylcholine in the prefrontal cortex, supporting the top-down attentional control that is impaired in ADHD. This is mechanistically distinct from stimulant medications (which primarily enhance dopamine and norepinephrine) but produces a complementary effect.
2. Dopaminergic and noradrenergic modulation — ADHD pathophysiology centrally involves prefrontal-striatal dopamine and norepinephrine signaling deficits. Bacopa modulates levels of dopamine and noradrenaline in addition to serotonin, supporting the catecholaminergic systems that stimulant medications target directly. The Bacopa effect is more subtle and gradual than stimulant action, but operates through related pathways.
3. BDNF, dendritic remodeling, and neurodevelopmental support — emerging evidence suggests that ADHD involves abnormalities of prefrontal dendritic morphology and synaptic connectivity, possibly related to delayed cortical maturation. Bacopa's structural effects on dendritic arborization (see the Memory and Learning page) may support the structural development of the prefrontal cortex during the years of greatest ADHD impact (ages 6 to 14).

The combination of these three mechanisms produces a slower, more diffuse, more structurally integrated effect than stimulant medications — one reason the clinical effects emerge over 12 weeks rather than within hours, and one reason the effects may be more lasting after discontinuation than the effects of stimulant medications.

Additional contributions come from Bacopa's GABAergic enhancement (reducing the hyperarousal and emotional reactivity that often accompany ADHD) and antioxidant effects (some evidence suggests oxidative stress contributes to ADHD pathophysiology, particularly in children with comorbid conditions).

Back to Table of Contents

Bacopa Compared to Stimulant Medications

An honest comparison of Bacopa with stimulant medications for pediatric ADHD must acknowledge that stimulants produce dramatically larger effects in the short term. Methylphenidate and amphetamine salts have effect sizes on the order of 1.0 standard deviation or larger on ADHD symptom measures — among the largest treatment effects in all of psychiatry. Bacopa's effect sizes are in the small-to-moderate range (0.2 to 0.5 standard deviations), with the cognitive effects more robust than the behavioral effects.

However, several considerations may favor Bacopa in specific clinical situations:

• Safety profile — Bacopa has minimal side effects (the most common is mild gastrointestinal upset). Stimulant medications produce appetite suppression and possible growth delay, insomnia, mood lability, increased blood pressure and heart rate, and the potential for dependence.
• Family preference — many families are deeply reluctant to medicate young children with controlled substances, particularly for prolonged periods. Bacopa offers a low-risk alternative for families with this preference.
• Adjunctive use — Bacopa can be combined with stimulant medications to support cognitive function during medication-free periods (weekends, summer breaks) or to allow lower stimulant doses with maintained efficacy.
• Persistent effect — stimulant effects vanish within hours of the last dose. Bacopa's effects (consistent with the structural-remodeling mechanism) appear to persist for weeks after discontinuation, potentially providing continued benefit during scheduled treatment breaks.
• Mild ADHD — children with mild ADHD where the symptom burden does not clearly warrant stimulant medication may have their symptoms adequately controlled by Bacopa plus behavioral intervention, avoiding pharmaceutical exposure altogether.
• Stimulant non-responders — approximately 20 to 30% of children with ADHD do not respond adequately to first-line stimulant medications or cannot tolerate the side effects. Bacopa offers a different mechanism that may produce benefit in these patients.

For severe ADHD with significant academic, social, or family impairment, stimulant medications remain first-line therapy and Bacopa is best positioned as an adjunct. For mild-to-moderate ADHD, Bacopa is a reasonable initial intervention to try, with escalation to stimulant medication if symptoms remain inadequately controlled after a 12 to 24 week trial.

Back to Table of Contents

Bacopa Combined with Stimulant Medications

For children already on stimulant medication who are seeking additional support, Bacopa is generally well tolerated and may provide complementary benefit. The mechanisms are distinct (Bacopa primarily cholinergic and structural; stimulants primarily dopaminergic and noradrenergic), so additive cognitive benefit is plausible. Several patterns of combined use are reasonable:

1. Bacopa added to existing stimulant therapy for additional cognitive enhancement, particularly in children who have partial response to stimulants and want incremental improvement without dose escalation.
2. Bacopa as a stimulant-sparing adjunct — in some children, addition of Bacopa allows reduction of the stimulant dose with maintained symptom control, reducing the burden of stimulant side effects.
3. Bacopa for medication-free periods — many families prefer to give weekend or summer breaks from stimulant medication. Bacopa's persistent effects can provide continued cognitive support during these breaks, easing the transition.
4. Bacopa during stimulant taper or discontinuation — for children whose ADHD is improving with developmental maturation and who are reducing stimulant medication, Bacopa can support cognitive function during the taper period.

Drug interactions between Bacopa and stimulant medications have not been formally studied, but no serious interactions have been reported clinically. Patients combining the two should monitor for additive cardiovascular effects (Bacopa can modestly lower heart rate; stimulants raise it) and for any new behavioral effects suggesting interaction. The pediatric prescriber should be informed of any natural supplements the child is taking.

Back to Table of Contents

Pediatric Safety Profile

The pediatric safety profile of Bacopa monnieri is excellent — one of the strongest arguments for its use in this population. Across the published pediatric trial literature (Negi 2000, Dave 2014, Kean 2016, plus several smaller open-label studies), the rate of side effects is low and the severity is minimal.

A systematic review of Bacopa monnieri in child and adolescent populations reported that only 2.3% of participants experienced mild side effects, with no serious adverse events across the published trial database. The most commonly reported side effects in children are:

• Gastrointestinal symptoms — mild nausea, abdominal cramping, increased bowel motility. These resolve with dose reduction or with taking Bacopa with a meal containing fat.
• Dry mouth — transient and self-limited
• Mild fatigue or sedation — rare; if it occurs, shift to morning-only dosing
• Increased thirst — uncommon but reported

Importantly, several side effects of stimulant medications that drive families to seek alternatives are not seen with Bacopa: no appetite suppression, no growth concerns, no insomnia (in fact, Bacopa often improves sleep quality), no mood lability or "rebound" emotional dysregulation, no dependence potential, and no cardiovascular effects beyond a possible modest reduction in heart rate.

Long-term safety data in pediatric populations remain limited — the longest published pediatric Bacopa trial is 6 months — but the herb's 3000-year history of traditional use in Indian children for cognitive and behavioral problems is reassuring, and the absence of any signal of serious adverse events in the published trials supports the favorable safety profile.

Back to Table of Contents

Pediatric Dosing and Practical Use

Pediatric Bacopa dosing has been less precisely studied than adult dosing, but the published trials converge on the following guidelines:

• Children ages 6 to 12 — 100 to 225 mg per day of standardized Bacopa extract (Bacognize or equivalent, 24-55% bacosides), typically given as 50 to 100 mg in the morning and 50 to 125 mg with lunch or after school.
• Adolescents ages 13 to 17 — 200 to 400 mg per day, with adult dosing (300 to 600 mg) appropriate for larger or older adolescents.
• Children under 6 — limited safety data, no published trials. Not recommended without specialist supervision.

Practical guidance:

1. Take with food containing fat — eggs, whole-fat yogurt, peanut butter, avocado. The lipophilic bacosides absorb significantly better with dietary fat.
2. Morning and lunch dosing is preferred over evening dosing. Bacopa is not typically sedating in children, but the cholinergic effect can be modestly activating in some individuals.
3. Use a standardized extract — either CDRI 08 (also marketed as KeenMind, BacoMind), Bacognize, or another standardized extract with documented bacoside content. Crude Bacopa powder varies enormously in potency and is not recommended for pediatric clinical use.
4. Commit to a minimum 12-week trial before judging effect, ideally 6 months. Earlier discontinuation will miss the benefit.
5. Reassess every 3 months with parent rating scales (the Conners' Parent Rating Scale is the gold standard for ADHD assessment) and with teacher feedback when possible. Document baseline so progress is measurable.
6. Combine with behavioral intervention — behavior therapy, parent training in behavioral management, and academic accommodations remain the foundation of ADHD treatment regardless of medication choice. Bacopa is most effective as part of a comprehensive approach.

Back to Table of Contents

What Parents Need to Know — The 12-Week Reality

The single most important concept for parents considering Bacopa for their child's ADHD is that this is not a stimulant medication and does not work like one. Parents accustomed to the dramatic, same-day effect of methylphenidate or amphetamine salts often try Bacopa, see no obvious effect in the first two or three weeks, and discontinue. This is a serious misreading of the herb's timeline.

Realistic expectations for the parent:

• Weeks 1 to 4 — no obvious change. The child may be slightly calmer or slightly more focused, but the changes are subtle enough that they could easily be attributed to other factors (school stability, parental attention, weather, sleep).
• Weeks 4 to 8 — possible early indications of improvement. The teacher may comment that the child is more on-task. Homework battles may be modestly less intense. Sleep quality may improve. The effect is still subtle and not dramatic.
• Weeks 8 to 12 — the benefit becomes more clearly noticeable. Improvements in attention, impulse control, and academic engagement become more reliably observable. This is the point at which most parents who continue Bacopa start to feel confident that it is working.
• Weeks 12 to 24 — the benefit continues to accumulate. Effects become more pronounced and more stable. This is the appropriate time for formal reassessment with parent rating scales.
• Beyond 24 weeks — benefits appear to be stable or continuing to slowly improve. Effects persist for weeks after discontinuation but appear to fade gradually over 1 to 3 months without continued dosing.

The patience required to see Bacopa work is, in some sense, a disadvantage compared to stimulant medications. In another sense, it is an advantage — the slow accumulation of structural neural changes is exactly the kind of intervention that may produce lasting developmental benefit, in contrast to the symptomatic-only effect of stimulants. Bacopa is not the right intervention for a family in crisis who needs immediate symptom control. It is the right intervention for a family willing to commit to a multi-month process of supporting their child's neurodevelopmental progress.

Back to Table of Contents

A Multimodal Strategy for Pediatric ADHD

Bacopa monnieri is best positioned as one component of a multimodal pediatric ADHD strategy that addresses multiple dimensions of the disorder simultaneously. A comprehensive approach for a child with mild-to-moderate ADHD might include:

1. Behavioral parent training and child behavior therapy — the evidence-based first-line non-pharmaceutical intervention. Available through psychologists, school counselors, and structured programs (Triple P, Parent-Child Interaction Therapy).
2. Academic accommodations — preferential seating, extra time on tests, broken-up assignments, regular movement breaks. Available through 504 plans or IEP processes in US schools.
3. Bacopa monnieri — 100 to 225 mg per day of standardized extract, with food, for at least 12 weeks. Discussed above in detail.
4. Omega-3 fatty acids — EPA-predominant fish oil (1000 to 2000 mg total EPA per day). Meta-analyses support a modest effect on pediatric ADHD symptoms. See our Omega-3 Fatty Acids page.
5. Zinc, iron, and magnesium — correct any deficiencies identified by laboratory testing. Iron deficiency in particular is associated with worsened ADHD symptoms and is correctable.
6. Sleep optimization — insufficient or poor-quality sleep dramatically worsens ADHD symptoms. Consistent bedtime routine, screen restriction in the hour before sleep, and adequate sleep duration for age are essential.
7. Physical activity — daily aerobic exercise produces measurable acute and chronic improvements in ADHD symptoms. School-based PE alone is insufficient; supplemental activity is important.
8. Limit processed foods and artificial additives — a subset of children with ADHD respond to elimination diets removing artificial colors and preservatives. The evidence base is mixed but the intervention is low-risk and worth trying.
9. Stimulant medication if needed — if the above interventions do not adequately control symptoms after 12 to 24 weeks of consistent implementation, addition of stimulant medication is appropriate. Bacopa and other natural interventions can be continued alongside.

For more on ADHD generally, see our ADHD page. For other natural cognitive interventions, see Methylene Blue for Cognitive Enhancement.

Back to Table of Contents

Key Research Papers

1. Negi KS et al. (2000). Clinical evaluation of memory enhancing properties of Memory Plus in children with attention deficit hyperactivity disorder. Indian Journal of Psychiatry. — PubMed
2. Dave UP et al. (2014). An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in children. Advances in Mind-Body Medicine 28(2):10-15. — PubMed
3. Kean JD et al. (2016). A randomized controlled trial investigating the effects of a special extract of Bacopa monnieri (CDRI 08) on hyperactivity and inattention in male children and adolescents. Phytomedicine 23(8):750-758. — PubMed
4. Kean JD et al. (2015). Systematic overview of Bacopa monnieri (L.) Wettst. dominant poly-herbal formulas in children and adolescents. Medicines (Basel) 4(4):86. — PubMed
5. Sarris J et al. (2011). Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. CNS Drugs 27(4):301-319. — PubMed
6. Usha PR et al. (2008). Effect of standardized extract of Bacopa monnieri (Bacognize) on cognitive functions of medical students: a six-week, randomized placebo-controlled trial. Indian Journal of Pharmacology. — PubMed
7. Sarris J, Kean J et al. (2011). Complementary medicines (herbal and nutritional products) in the treatment of attention deficit hyperactivity disorder (ADHD): a systematic review. Complementary Therapies in Medicine 19(4):216-227. — PubMed
8. Pellow J, Solomon EM, Barnard CN (2011). Complementary and alternative medical therapies for children with attention-deficit/hyperactivity disorder (ADHD). Alternative Medicine Review 16(4):323-337. — PubMed
9. Rezvani AH, Levin ED (2002). Cognitive effects of nicotine. Biological Psychiatry 49(3):258-267 (relevant to the cholinergic mechanism shared by Bacopa and nicotinic agents). — PubMed
10. Singh HK, Dhawan BN (1997). Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera Linn (Brahmi). Indian Journal of Pharmacology 29:S359-S365. — PubMed
11. Aguiar S, Borowski T (2013). Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Research 16(4):313-326. — PubMed
12. Kongkeaw C et al. (2014). Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. Journal of Ethnopharmacology 151(1):528-535. — PubMed

PubMed Topic Searches

• PubMed: Bacopa ADHD children
• PubMed: Bacopa pediatric safety
• PubMed: Natural ADHD treatments
• PubMed: CDRI 08 KeenMind ADHD
• PubMed: Brahmi attention hyperactivity

Back to Table of Contents

Connections

• Bacopa Monnieri Overview
• Bacopa Benefits Hub
• Bacopa for Memory
• Bacopa for Anxiety
• Bacopa for Neuroprotection
• ADHD
• Anxiety
• Depression
• Methylene Blue for ADHD
• Ashwagandha
• Rhodiola Rosea
• Ginkgo Biloba
• Omega-3 Fatty Acids
• Gut-Brain Axis
• All Herbs

Back to Table of Contents